Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Motohiro Tamiya

Showing results (141-150 of 192) with videos related to

Pageof 20
Sort By:
JTO Clinical and Research Reports|June 30, 2022
Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort StudyHayato Kawachi, Motohiro Tamiya, Yoshihiko Taniguchi, et al.
European Journal of Cancer (Oxford, England : 1990)|September 3, 2025
Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter studyAkihiro Tsukaguchi, Kinnosuke Matsumoto, Akihiro Tamiya, et al.
Cancer Research Communications|September 25, 2025
Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1-Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter StudyKohei Shitara, Motohiro Tamiya, Kyoichi Okishio, et al.
Cancer Research Communications|January 5, 2024
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer CohortMakoto Nishio, Shuji Murakami, Hisato Kawakami, et al.
Thoracic Cancer|September 13, 2022
Clinical application of comprehensive genomic profiling panel to thoracic malignancies: A single-center retrospective studyKei Kunimasa, Naotoshi Sugimoto, Takahisa Kawamura, et al.
Cancer Genetics|January 10, 2020
Rapid progressive lung cancers harbouring multiple clonal driver mutations with big bang evolution modelKei Kunimasa, Yosuke Hirotsu, Harumi Nakamura, et al.
Translational Lung Cancer Research|December 10, 2025
Selecting optimal immunotherapy based on inflammation in stage IV PD-L1 ≥50% gene mutation-negative non-small cell lung cancer: pembrolizumab monotherapy versus combination chemoimmunotherapyYusuke Kunimatsu, Naoya Nishioka, Tadaaki Yamada, et al.
Journal for Immunotherapy of Cancer|February 15, 2024
Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancerRyota Shibaki, Daichi Fujimoto, Tsukasa Nozawa, et al.
Lung Cancer (Amsterdam, Netherlands)|January 9, 2025
Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learningDaichi Fujimoto, Ryota Shibaki, Keiichi Kimura, et al.
Investigational New Drugs|December 1, 2019
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort studyHayato Kawachi, Motohiro Tamiya, Akihiro Tamiya, et al.
Pageof 20

Showing results (141-150 of 192) with videos related to

Sort By:
Pageof 20
JTO Clinical and Research Reports|June 30, 2022
Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort StudyHayato Kawachi, Motohiro Tamiya, Yoshihiko Taniguchi, et al.
European Journal of Cancer (Oxford, England : 1990)|September 3, 2025
Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter studyAkihiro Tsukaguchi, Kinnosuke Matsumoto, Akihiro Tamiya, et al.
Cancer Research Communications|September 25, 2025
Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1-Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter StudyKohei Shitara, Motohiro Tamiya, Kyoichi Okishio, et al.
Cancer Research Communications|January 5, 2024
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer CohortMakoto Nishio, Shuji Murakami, Hisato Kawakami, et al.
Thoracic Cancer|September 13, 2022
Clinical application of comprehensive genomic profiling panel to thoracic malignancies: A single-center retrospective studyKei Kunimasa, Naotoshi Sugimoto, Takahisa Kawamura, et al.
Cancer Genetics|January 10, 2020
Rapid progressive lung cancers harbouring multiple clonal driver mutations with big bang evolution modelKei Kunimasa, Yosuke Hirotsu, Harumi Nakamura, et al.
Translational Lung Cancer Research|December 10, 2025
Selecting optimal immunotherapy based on inflammation in stage IV PD-L1 ≥50% gene mutation-negative non-small cell lung cancer: pembrolizumab monotherapy versus combination chemoimmunotherapyYusuke Kunimatsu, Naoya Nishioka, Tadaaki Yamada, et al.
Journal for Immunotherapy of Cancer|February 15, 2024
Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancerRyota Shibaki, Daichi Fujimoto, Tsukasa Nozawa, et al.
Lung Cancer (Amsterdam, Netherlands)|January 9, 2025
Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learningDaichi Fujimoto, Ryota Shibaki, Keiichi Kimura, et al.
Investigational New Drugs|December 1, 2019
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort studyHayato Kawachi, Motohiro Tamiya, Akihiro Tamiya, et al.
Pageof 20